LYON, France, Aug. 26, 2010 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it will expand into the rapidly growing Chinese healthcare market with its Albatherm HIFU device for the treatment of prostate cancer. Ablatherm HIFU will be distributed throughout China by Shaw Han Biomedical Co. Ltd. This exclusive distribution agreement underscores EDAP’s global expansion strategy for HIFU in what is the fastest growing medical device market. With the largest population in the world, China represents a significant market for prostate cancer treatment as cancer detection rates rise, awareness of treatment options increases and the expanding aging population garners greater access to healthcare. It is an opportune time to commence the regulatory and marketing process in China for EDAP’s robotized, quality-of-life preserving device.
